Clinical Trial

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)

Study acronym: KRASCENDO 3
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the efficacy of divarasib compared with investigator's choice of immunotherapy (pembrolizumab or nivolumab) or observation in participants with resected Kirsten rat sarcoma viral oncogene homolog glycine 12 to cysteine (KRAS G12C)-positive Stage II-IIIB NSCLC, regardless of tumor programmed death-ligand 1 (PD-L1) status, who have not achieved pathologic complete response (pCR) following neoadjuvant chemoimmunotherapy.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-11
Trial Details
NCT Number NCT07541170
Lead Sponsor Hoffmann-La Roche
Conditions Non-small Cell Lung Cancer
Enrollment 400 participants
Start Date 2026-09-01
Primary Completion 2032-01-31 (estimated)
Study Completion 2035-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-10